APA (7th ed.) Citation

SW, H., C, T., A, W., E, G., M, L., AJ, A., . . . F, B. (2019). The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. Haematologica, 104(8), 1633. https://doi.org/10.3324/haematol.2018.211011

Chicago Style (17th ed.) Citation

SW, Hicks, et al. "The Novel CD19-targeting Antibody-drug Conjugate HuB4-DGN462 Shows Improved Anti-tumor Activity Compared to SAR3419 in CD19-positive Lymphoma and Leukemia Models." Haematologica 104, no. 8 (2019): 1633. https://doi.org/10.3324/haematol.2018.211011.

MLA (9th ed.) Citation

SW, Hicks, et al. "The Novel CD19-targeting Antibody-drug Conjugate HuB4-DGN462 Shows Improved Anti-tumor Activity Compared to SAR3419 in CD19-positive Lymphoma and Leukemia Models." Haematologica, vol. 104, no. 8, 2019, p. 1633, https://doi.org/10.3324/haematol.2018.211011.